Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

05. Juni 2013 08:00 ET | Quelle: Receptos, Inc.

Receptos Provides Update on Progress of Lead Product Candidate RPC1063

Successfully Completes Thorough QT Study Obtains Special Protocol Assessments (SPAs) From FDA for Phase 3 Trials in Relapsing Multiple Sclerosis SAN DIEGO, June 5, 2013 (GLOBE NEWSWIRE) --...
29. Mai 2013 16:30 ET | Quelle: Receptos, Inc.

Receptos to Present at Jefferies 2013 Global Healthcare Conference

SAN DIEGO, May 29, 2013 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today...
15. Mai 2013 16:05 ET | Quelle: Receptos, Inc.

Receptos to Deliver Scientific Presentations at Digestive Disease Week 2013 About the Therapeutic Role of RPC1063 in Inflammatory Bowel Disease

SAN DIEGO, May 15, 2013 (GLOBE NEWSWIRE) -- Receptos (Nasdaq:RCPT) today announced that Company personnel will deliver three scientific poster presentations about RPC1063 at the Digestive Disease Week...
14. Mai 2013 21:39 ET | Quelle: Receptos, Inc.

Receptos Announces Completion of Initial Public Offering of Common Stock

SAN DIEGO, May 14, 2013 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today...
08. Mai 2013 19:02 ET | Quelle: Receptos, Inc.

Receptos Announces Pricing of Initial Public Offering of Common Stock

SAN DIEGO, May 8, 2013 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today...

Vorherige Seite